Three Giants of Medicine，Two of them! Postering medicine and Guang medicine、Ha Yao、Chongqing Pharmaceutical and others signed an agreement，China Resources has also recently launched the overall listing project。In the second half of the year，The pharmaceutical circulation industry is fierce and fiercely fierce。Three giants in the pharmaceutical commerce may be launched again!

 

  June 27，China Resources Pharmaceutical Group (hereinafter referred to as China Resources) overall listing prospectus disclosed in the Hong Kong Stock Exchange，According to media shop disclosure，Grade Pharmaceuticals seeking financing of more than $ 1 billion，May be as early as September this year。But about the time of listing and the plan to be raised，China Resources did not give media response。

 

  China Resources is a pharmaceutical giant currently second only to the National Medicine Group，Its main business is divided into three major sections，One is the pharmaceutical，The second is the distribution of medicine，Third is the retail of drugs。There are three A -share listed companies China Resources Three Nine、China Resources Shuanghe、East Ejiao，In addition, it also owns China Resources Pharmaceutical Commercial Group、China Resources Zizhu Pharmaceutical and other companies。

 

  Although this is the overall listing of China Resources，but，Among them, China Resources strategies and determinations in pharmaceutical business。

 

  In the prospectus，China stake online sports bettingstake sports betting appResources Represents，In the field of pharmaceutical distribution and pharmaceutical retail，Company intends to acquire the large distribution network through mergers，Cover the whole country from 2020。This is also one of the uses for raised funds for this time，It is used for the above acquisition，At present, it has been in contact with multiple acquisitions target，But there is no final acquisition intention。

 

  Shi Lichen, the founder of Beijing Dingchen Medical Management Consultation Center, expressed his explanation to Sai Bailan，In the first half of this year，Due to GSP Flying Inspection、The drug supervision department's implementation of the major remediation industry and the implementation of the two -vote system，Some pharmaceutical commerce publicly closed or wants to withdraw from the market，For circulating enterprises，This is a rare time to grab the site，In the second half of the year，The pharmaceutical circulation industry will have a climax of fighting。For the breadth and depth of the distribution rate, it is necessary to improve China Resources，It will also be a critical period。

 

  China Resources Pharmaceutical: The market share is only half of the industry leader

 

  Analysts said，China Resources Pharmaceutical and Sinopharm Holdings are all medical circulation giants，But the current Chinese medicine holding accounts for a larger advantage，Whether it is the distribution coverage and market share，All are higher than China Resources。

 

  Since the new medical reform，Pharmaceutical business giants began to actively siege in various provinces，Continue to expand its business territory through mergers and acquisitions。In the medical industry，China Resources is not like Chinese medicine and medicine，belonging to the latecomer，But through a series of mergers and acquisitions，Especially after the successful acquisition of Beijing medicine，China Resources Pharmaceutical Business (Responsible for medical wholesale business sales business company，referred to as China Resources Pharmaceutical) Different troops protruding，Successfully overtake the medicine，Become the second largest pharmaceutical business giant after Sinopharm Group。

 

  Although a series of mergers and acquisitions make China Resources Pharmaceutical's arms rise，but，In terms My stake betting appof stake betting appoverall strength,，There is still a certain gap in China Resources and Chinese medicine。

 

  According to China Resources's prospectus，2015，Calculated according to the income，There are five major pharmaceutical distribution giants in China，China Resources Rank No. 2，Market proportion is 8.1%，Rank No. 1 company，The prospectus is called by Company A，But according to the "2015 Pharmaceutical Distribution Industry Operation Statistical Analysis Report" released by the Ministry of Commerce，Its market share is 19.6%。More than twice the China Resources Medicine。

 

  Ranking Third Company B，The "2015 Drug circulation Industry Operation Statistical Analysis Report" issued by the Ministry of Commerce should refer to medicine，Its market share is 7.3%，There is only a gap between 0.8%percentage point between China Resources。

 

  The medicine has been done

 

  May 12，Six domestic pharmaceutical giants Guangyao Pharmaceutical Group, Guangyao Pharmaceutical Baiyun Mountain、Shanghai Medicine、Nanjing Medicine、Harbin Pharmaceutical Co., Ltd.、Tianjin Medicine、Chongqing Pharmaceuticals signed the "Memorandum of Cooperation for Cooperation Pharmaceutical Platform" in Shanghai，Six Party intends to jointly fund the establishment of a platform company，Communication through cooperation、Reduce the entry threshold of its own variety，Improve the ability to introduce and negotiate the ability to introduce six -party products，Reduce corporate procurement、Operating cost。

 

  After taking the medicine second only to China Resources，China Resources Pharmaceutical pressure doubles。Industry insiders said，The pharmaceutical circulation industry will resume smoke，China Resources Pharmaceutical will make decisive shots，Resisting 6 major pharmaceutical leaders such as Shang medicine，Consolidate its industry status，At the same time, you will get up and catch up，Challenge the status of the Chinese Medicine Group in the circulation industry。

 

  Favorite objects of China Resources Commerce

 

  In the prospectus，China Resources Pharmaceutical Representation，The Organization of the M & A in their business field is with the hospital、Regional leading pharmaceutical distribution companies and retail companies with customers with solid relationship with other medical institutions。

 

  Since last year，Medicine circulation starts frequently，This year，More rectification in circulation industry。May，The State Food and Stake Sports BettingStake Sports BettingDrug Administration issued a self -examination announcement of a drug wholesale enterprise，Require all drug wholesale companies to be reliable、illegal operation and other behaviors for self -examination。

 

  People in the pharmaceutical circle, Hongtu, recognize it，The country is close to 13,000 GSP pharmaceutical companies，The Great Remediation of the State Drug Administration on the circulation industry，Add two -vote system，Pharmaceutical companies (about 6,000), which will be closed in the future, is not impossible。

 

  The State Council said in the focus of the medical reform in 2016，The so -called two -vote system，refers to a vote from drug production enterprises to distribution，From the delivery enterprise to the hospital is one vote。Although there have been various versions of the State Council's Medical Reform Office on the implementation of the two -vote system，but，Before the policy was introduced，We are not good at speculation，but，There is no doubt that it is，The two -vote system will have a great impact on the circulation industry。

 

  Who will be China Resources competitors?

 

  Shi Lichen, the founder of Beijing Dingchen Medical Management Consultation Center, pointed out in an interview with the media，The two -vote system only allows single -level distributors to sell pharmaceutical products from manufacturers，Pharmaceutical Factory issues votes to professional operators with distribution services and pharmaceutical affairs management，Specialty to assist in the maintenance and business management of pharmacy terminals，Large pharmaceuticals will benefit from this。

 

  Red soil representation，Fujian Province executes two -vote，13 large distribution companies left in 5 years，The subsidiaries that are merged will also be about 100。The time of being shuffled by small and medium -sized pharmaceutical companies began。

 

  Another person in the pharmaceutical industry said，Under the background of the major rectification of the circulation industry，Add two -vote execution，The merger and integration of the pharmaceutical circulation industry will speed up。The addition of the medical industry giants will accelerate this process。Three Giants in the Medicine Circulation Industry，There are already two faucets who have shot，Chinese medicine is estimated to not stand by。

 

  Shi Lichen said，In addition to the national medicine giant，Some provincial pharmaceutical companies will also become a strong competitor of China Resources。

 

 

 

stake betting appThrough the prospectus，My stake betting appYou can clearly see the layout of China Resources Pharmaceutical in the field of pharmaceutical distribution。

 

As of the end of December 2015，China Resources Pharmaceutical has established 2769 distributors，and operate a national distribution network composed of 114 subsidiaries and 111 logistics centers，Strategic covering 19 provinces and cities in China。

 

Where，Medical distribution business mainly sells directly from hospitals and other medical institutions，In 2015, it accounted for 61.1%of China Resources Pharmaceutical's external sales。Under the business model directly sold to hospitals and other medical institutions，Compared to the sales to other distributors, it generates a higher profit margin。As of the end of 2015，China Resources Pharmaceutical has already sold products directly to 1011 third -level hospitals and 3022 secondary hospitals and 40778 primary medical institutions。